Affini-T Therapeutics

Ver el organigrama con sus 12 ejecutivos principales

Biografías más buscadas en Affini-T Therapeutics

• Jak Knowles, Co-Founder, President, Chief Executive Officer and Di...
• Lucio Iannone, Director
• Arjun Goyal, Director

Recientes movimientos de ejecutivos en Affini-T Therapeutics

• Kathy Bergsteinsson, se ha incorporado a la empresa como Chief Financial Officer  (noticia publicada el 14 de noviembre de 2023).

Crear su alerta
para seguir los movimientos de los ejecutivos en Affini-T Therapeutics.

Affini-T Therapeutics tiene 2.280 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnología

• Metsera acaba de anunciar una recaudación de fondos de 290 millones de dólares. (publicado el 23 de abril de 2024).
• Histogen has filed for bankruptcy protection  (publicado el 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado el 18 de abril de 2024).

Otros contactos sugeridos en el sector Biotecnología

• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics
• Vik Bajaj - Director en Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board en Sensorion

Saber más sobre el sector Biotecnología >

Últimos comunicados de prensa de Affini-T Therapeutics

• Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Affini-T Therapeutics
• Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting | Affini-T Therapeutics
• Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Affini-T Therapeutics
• Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer | Affini-T Therapeutics
• Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Affini-T Therapeutics
• Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
• Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
• A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
• View more press releases Close

Redes sociales sobre Affini-T Therapeutics

• Affini-T Therapeutics en Wikipedia, Google News y Yahoo Finance
• Affini-T Therapeutics en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Jak Knowles

Llame a Affini-T Therapeutics al +1 619...

Ver el organigrama

Register to receive your alert

Señalar un error